Changyao Group(SZ:300391) 梧桐树下V·2026-03-18 16:05Core Viewpoint - The article discusses the administrative penalties imposed on Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) due to false disclosures in its annual reports from 2021 to 2023, leading to significant fines and the termination of its stock listing [1][25]. Group 1: Company Violations - From 2021 to 2023, *ST Changyao's subsidiary companies fabricated inventory and sales documents, resulting in inflated revenues of CNY 215.32 million, CNY 283.74 million, and CNY 233.63 million, which accounted for 9.12%, 17.57%, and 19.51% of the reported revenues for those years respectively [3][4]. - The total inflated profit for the same period was CNY 56.40 million, CNY 63.38 million, and CNY 43.71 million, representing 35.62%, 88.23%, and 6.42% of the reported profit totals [3][4]. Group 2: Responsible Individuals - A total of 14 individuals were held accountable for the violations, including key figures such as: - Luo Ming, who was directly responsible for the financial misconduct and received a lifetime ban from the securities market along with a fine of CNY 5 million [11]. - Yang Zhenghui, who was fined CNY 3 million and banned for 10 years due to serious violations [11]. - Other individuals received fines ranging from CNY 150,000 to CNY 300,000 for their roles in the false reporting [13][14][15][16][17][18][19][20][21][22][23][24]. Group 3: Stock Termination - Due to the continuous false disclosures in its annual reports, *ST Changyao's stock will be forcibly delisted, as it violated the Shenzhen Stock Exchange's rules regarding significant misconduct [25]. - The company received a notice of termination of its stock listing on March 12, 2026, with trading expected to cease by April 10, 2026 [25].